Leukemia is a malignancy of both blood and bone marrow followed by uncontrolled
proliferation of transformed hematopoietic cells. Acute myeloid leukemia (AML) is a
group of hematological diseases, phenotypic and genetically heterogeneous, characterized
by abnormal accumulation of blast cells in the bone marrows and peripheral blood. JAK2
kinase is a member of a family of tyrosine kinases involved in cytokine receptor
signaling. JAKs contain many domains and kinase domain is vital for JAK activity, since
it add phosphate groups to proteins. JAK2 exon 14 is sequenced and analyzed for the
study of its role and prognostic significance in Pakistani AML patients. The main
objective of this research is to put emphasis on different clinical and hematological
parameters, their association with mutation in JAK2 gene exon 14 and its prognostic
significance. In present study, all sequences are analyzed by polymerase chain reaction
(PCR), Sanger sequencing techniques, Geneious prime (2019) and different statistical
tests. Out of 31 AML patients, 8 show mutations in exon 14 of JAK 2 gene with amino
substitution of valine to glutamic acid. Only normal spleen size shows significant
association in current study having p value less than 0.05. Prognostic implications of
JAK2 are still unclear. These findings helped us to study prognosis of JAK2 and its
association with hematological and clinical parameters among AML patients.